Retatrutide: what a large Phase 3 weight study found

What the weight studies found first

Retatrutide remains an investigational drug without FDA approval. Phase 3 means a large, late test before approval. Authorized clinical trials are the route for supervised human use; retatrutide cannot be prescribed by a telehealth service.

Retatrutide acts like three natural hormones. One helps insulin and can lower your hunger. The next helps insulin after meals. The last may increase the body's fuel use and release liver sugar.

The earlier Phase 2 weight study lasted 48 weeks. At the highest dose, people lost 24.2% of their weight. That is about 58 lbs for a 240-lb person.

People in the placebo group received a dummy shot and lost 2%. TRIUMPH-1 later found 28.3% at 80 weeks. The TRIUMPH-1 average can't foretell your own result.

This site explains what the studies measured. It doesn't sell retatrutide or give medical advice. No help is offered for finding the drug outside a study. The effects and safety page keeps study results apart from personal reports.

What Retatrutide changed in the studies

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide engineered to activate three hormone receptors simultaneously — GLP-1R, GIPR, and GCGR — producing complementary effects on appetite, insulin secretion, and energy expenditure. The compound was developed by Eli Lilly and Company and entered clinical trials as an investigational agent for obesity and type 2 diabetes.

In the 2023 Phase 2 obesity trial published in the New England Journal of Medicine, participants randomized to 12 mg once weekly achieved 24.2% mean body weight reduction at 48 weeks, compared to 2.1% with placebo ^[1]. The Phase 3 TRIUMPH-1 trial extended that trajectory: at 80 weeks, the 12 mg arm reached 28.3% mean weight loss — 70.3 lbs — with 45.3% of participants achieving 30% or greater weight loss, a threshold historically associated with bariatric surgery ^[5].

Beyond weight: the compound's liver data are striking. In a Phase 2a trial published in Nature Medicine, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), and 86% of the 12 mg group achieved normal liver fat (below 5%) by 48 weeks ^[3].

Retatrutide is not FDA approved. It remains investigational, with no routine prescription route. Enrollment in an authorized clinical trial is the route for supervised human use; products labelled for research are also sold, but those labels do not authorize use in people. The Phase 3 TRIUMPH program is ongoing, encompassing obesity, type 2 diabetes, osteoarthritis, and cardiovascular outcomes trials enrolling more than 5,800 participants. This site documents the published research record.

Retatrutide's trial-only status is worth spelling out concretely, because a name like "Clinic Retatrutide" invites an obvious question: what clinic? None, in the ordinary sense. Supervised human use of retatrutide belongs in an authorized clinical trial, with a study protocol and informed consent, rather than an ordinary prescription visit. A trial tests an investigational drug; prescribing a compounded medicine is a separate form of care and does not give that medicine FDA approval. For a present-day example in the same broader drug class, Promise Peptides (mypromise.com) prescribes compounded tirzepatide, which requires a prescription; it does not offer retatrutide. A clinician licensed in the United States assesses each person's case and may decline to prescribe. For that prescription care, only U.S. patients can be considered; options differ across states and treatments. FDA-approved tirzepatide exists, while the compounded preparation has not been approved by the FDA. Retatrutide's investigational status excludes it from ordinary telehealth prescribing and walk-in prescription visits. The distinction is in the purpose of the visit: a trial enrolls participants in a fixed research design, while a prescription consultation considers an individual's circumstances. For retatrutide, a consultation cannot substitute for trial enrollment.

What keeps Retatrutide in the blood

Eli Lilly made Retatrutide for one weekly shot. It is a lab-made protein with many linked parts. The links help the drug copy natural hormones.

Its lab weight is about 4,731 daltons. A dalton is a unit for something too small to see. The lab weight does not set the shot amount. The drug has a 6-day half-life ^[19]. That span tells when blood has lost half.

Three changed parts sit at spots 2, 20, and 13. Those changes slow the body's breakdown of the drug. The spot numbers only mark where the lab changed the chain. A fatty attachment also helps the drug stay in blood.

Some reports call the drug GLP-3 or triple GLP. The number means retatrutide works in three hormone-like ways. The nickname isn't a formal medical name. It says nothing about safety or results.

The main Phase 2 papers appeared in 2023. One medical journal printed the weight study ^[1]. Another printed the diabetes study ^[2]. Eli Lilly announced Phase 3 results in 2025. Those were TRIUMPH-1 and TRIUMPH-4 ^[5][8]. TRIUMPH-1 studied weight, while TRIUMPH-4 also studied knees.

What Retatrutide changed in people's bodies

Phase 2 studies checked weight, belly fat, liver fat, blood pressure, blood sugar, and blood fats. These were mid-stage tests in people. Larger doses tended to bring larger changes.

Adults with obesity lost a mean 24.2% at 48 weeks on 12 mg ^[1]. Adults with type 2 diabetes lost 16.94% at 36 weeks ^[2]. Another review put the 12 mg result at 22.10% more loss than placebo ^[9]. A mean can't predict your own loss.

A liver study found 82.4% less liver fat at 24 weeks. A special scan measured the share of liver fat. Sanyal reported the work in 2024 ^[3]. By 48 weeks, 86% of the 12 mg group had normal liver fat.

Another body scan measured deep belly fat. That fat fell by as much as 31.4% at 36 weeks. Coskun reported the Phase 2 diabetes work in 2025 ^[6]. The scan also estimated muscle and other tissue.

Blood tests changed by week 48. Cholesterol outside the protective kind fell 26.9%. Another common blood fat fell 40.6%. Blood pressure fell as much as 11.8 mmHg. A less familiar blood fat fell 38.0%. Doctors heard the Phase 2 report at a heart meeting in 2024 ^[11].

The three-month blood sugar test fell 2.02% at 36 weeks in the 12 mg group. In that Phase 2 diabetes study, 82% reached a result of 6.5% or less ^[2]. That test shows your recent average blood sugar.

Who made Retatrutide and what remains open

Eli Lilly and Company made retatrutide. The company's name appears on every listed study. ClinicalTrials.gov lists the Phase 2 weight study.

The public list also has the type 2 diabetes study. Another entry covers the Phase 3 TRIUMPH-1 study. Each entry names the places and study contacts.

A court sent an FDA choice back for review in September 2025. The FDA must choose which legal review path fits this drug. One legal route covers ordinary chemical drugs. The other covers drugs made from living material. Eli Lilly challenged the first choice. The FDA hadn't settled it by May 2026. The answer may affect later prices and copies.

What Retatrutide is being tested for

The main studies ask whether retatrutide helps adults lose weight. They include people with a BMI of 30 or more. Some include a BMI of 27 plus another health problem. BMI compares weight with height.

Other studies ask about:

• Blood sugar in type 2 diabetes, with Phase 2 done and Phase 3 under way
• Fatty liver disease, with Phase 2a done and Phase 3 planned
• Knee arthritis pain after weight loss, with TRIUMPH-4 Phase 3 news in 2025
• Sleep apnea, now in a TRIUMPH Phase 3 study
• Heart attacks, strokes, and heart-related deaths in TRIUMPH-3, with no answer by May 2026

In Phase 2, the retatrutide dosage studies covered 1 mg through 12 mg once a week under the skin. Phase 3 studies test 4, 9, and 12 mg. The clinical trial data page lists the papers.